We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mersana Therapeutics Inc | NASDAQ:MRSN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 2.98% | 3.46 | 3.36 | 6.00 | 3.63 | 3.42 | 3.52 | 1,189,390 | 05:00:04 |
Baird 2017 Global Healthcare ConferenceDate/time: Wednesday, September 6th at 3:10 p.m. E.T.Location: New York, NY
Cantor Fitzgerald Global Healthcare ConferenceDate/time: Wednesday, September 27th at 3:25 p.m. E.T.Location: New York, NY
Leerink Partners Roundtable Series: Rare Disease & Immuno-OncologyDate/time: Thursday, September 28th at 8:00 a.m. E.T.Location: New York, NY
Live webcasts of the presentations will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 60 days following the presentations.
About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company expects that its second product candidate, XMT-1536, will enter clinical trials in early 2018. In addition, multiple partners are using Mersana’s leading platform to advance their ADC pipelines.
Media Contact Paul Kidwell paulkidwell@comcast.net 617-680-1088 Investors Contact Stern Investor Relations, Inc. Christina Tartaglia Christina@sternir.com (212) 362-1200
1 Year Mersana Therapeutics Chart |
1 Month Mersana Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions